Previous 10 | Next 10 |
BOSTON, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company’s partner in China, Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), received approval from the National Medical Products Administration (NMPA) of China of NUZYRA ...
Zai Lab (NASDAQ:ZLAB) perks up 3.5% premarket after announcing that the China National Medical Products Administration (NMPA) has approved its New Drug Application (NDA) for NUZYRA (omadacycline), an antibiotic with both oral and intravenous formulations, for the trea...
NUZYRA demonstrated efficacy against common pathogens in three Phase 3 studies, including pathogens resistant to other antibiotic classes as a potential best-in-class tetracycline NUZYRA is Zai Lab’s fourth new product approval and the first outside oncology SHANGHA...
News that the Federal Reserve was primed to start fighting inflation sent U.S. stocks sharply higher on Wednesday. While monetary policy served as the main driver of trading, the session still featured a wide range of single-stock stories. Pfizer (NYSE:PFE) represented one of the standout per...
Shares of BeiGene (NASDAQ: BGNE) and Zai Lab (NASDAQ: ZLAB) were down by 13% and 15%, respectively, as of 2:40 p.m. ET Wednesday. These two Chinese biotechs were getting crushed over fears that they might eventually be forced to delist from the Nasdaq stock exchange. Ris...
Caught up in a political battle, U.S.-listed Chinese biotechs have extended their pre-market losses into afternoon trading. Biden administration is said to be weighing stricter sanctions on China’s largest chipmaker, Semiconductor Manufacturing International Corp. (OTCQX:SMICY), and pl...
Gainers: Biofrontera (NASDAQ:BFRI) +26%, Gemini Therapeutics (NASDAQ:GMTX) +19%, Vir Biotechnology (NASDAQ:VIR) +14%, Mesoblast (NASDAQ:MESO) +14%, Tandem Diabetes Care (NASDAQ:TNDM) +10% Losers: Atai Life Sciences (NASDAQ:ATAI) -24%, Alzamend...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the National Reimbursement Drug List (NRDL) released by China&...
Zai Lab (NASDAQ:ZLAB) announces that the Phase 3 PRIME study of Zeluja (niraparib) as maintenance therapy met its primary endpoint. Shares up 2.9% premarket at $74.50. Zeluja demonstrated a statistically significant and clinically meaningful progression-free survival benefit wi...
News, Short Squeeze, Breakout and More Instantly...
First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study Zai Lab Limited (NASDAQ: Z...
Manuscript represents the first publication from China’s gynecology oncology field to be published in Cell Publication highlights first-time learnings about the landscape of ovarian cancer microenvironment stratified by HRD and how a PARP inhibitor perturbs it Data suggest ...
2024-07-05 18:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...